Skip to main content
. 2022 Nov 23;12:949111. doi: 10.3389/fonc.2022.949111

Table 1.

Clinical parameters of patients.

Variables Training cohort (n =90) P Validation cohort (n = 39) P
ADC (n=61) SCC (n=29) ADC (n=26) SCC (n=13)
Age (year) 62.03 ± 9.06 66.27 ± 8.97 0.040 60.08 ± 9.96 63.62 ± 9.81 0.300
Gender <0.001* 0.022*
 Male 30 28 11 12
 Female 31 1 15 1
Smoking <0.001* 0.029*
 Never 15 15 7 9
 Ever/Always 46 10 19 4
Spiculation 0.004* 0.307
 Yes 48 13 16 5
 No 13 14 10 8
lobulation 0.930 0.397
 Yes 53 25 24 10
 No 8 4 2 3
null Vacuole 0.628 0.687
 Yes 12 7 7 2
 No 49 22 19 11
tumor location 0.030* 0.687
 Peripheral 53 25 24 10
 Central 8 4 2 3
pleural effusion on the tumor side 0.738 0.852
 Yes 5 3 2 2
 No 56 26 24 11
pericardial effusion 0.274 0.608
 Yes 5 0 1 1
 No 56 29 25 12
distant metastasis 0.016* 0.420
 Yes 21 3 7 2
 No 40 26 19 11
CEA(ug/L) 3.18
(1.76,9.90)
2.60
(2.02,5.20)
0.610 2.33
(1.63,5.50)
3.28
(1.37,4.37)
0.532
NICAP 0.09
(0.04,0.18)
0.08
(0.01,0.14)
0.223 0.12
(0.05,0.20)
0.05
(0.03,0.12)
0.136
λHUAP 1.39 ± 1.03 1.14 ± 1.02 0.267 1.86 ± 1.40 1.01 ± 0.65 0.044*
NICVP 0.28
(0.16,0.46)
0.19
(0.08,0.33)
0.019* 0.37
(0.21,0.47)
0.17
(0.03,0.23)
0.003*
λHUVP 1.88 ± 1.07 1.21 ± 0.82 0.004* 2.17 ± 1.13 0.96 ± 0.69 0.001*

Data are the proportion of sample size, mean value ± SD or median (interquartile range). P values were the results of univariate analysis of each parameter, *p < 0.05.

AP, arterial phase; VP, venous phase.